Research Article of Open Journal of Gastroenterology and Hepatology
Study the Role of Combined M2-Pyruvate kinase, Calprotectin and Occult Blood Test as Fecal Biomarkers for Early Detection of Colorectal Cancer
Atef Abo El-Soud Ali1, Mohamed Gamal El Helbawy2, Huda Saad Elmehily3, Emad Mohamed Salem4, Ahmed Abo Zaid Ahmed5
1Proffessor of Tropical Medicine(Menoufia University), 2Lecturer of clinical Pathology(Menoufia University) 3Tropical Medicine Department (Menoufia University), 4Head of Gastroenterology department of NJCH ( New Jeddah Clinic Hospital ) KSA, 5Lecturer of Tropical Medicine(Menoufia University)
Background and study aim: One of the main requirements of biomarkers for detecting CRC is that it must allow detection of the disease at earlier stages. The current study is designed to investigate the role of combined M2-Pyruvate kinase, Calprotectin, and Fecal occult blood test measurements as fecal diagnostic biomarkers for early detection of colorectal cancer. Patients & Methods: Total number of 72 subjects (48 patients and 24 healthy controls) were included in the study. Patients with cancer colon and patients with organic non-malignant colorectal lesions were recruited from Oncology and Gastroenterology Outpatient Clinics and Inpatient Department Menoufia University Hospital. Results: There was a highly significant difference between studied groups regarding age and gender (P> 0.001), cancer colon was higher among old age (mean ± SD is 58.96±6.3) and males (70.8%), There was a highly significant difference between studied groups regarding Hb, CRP and ESR (P >0.001); lowest Hb level was detected in cancer group (8.7±1.7). On the other hands highest CRP and ESR levels were in cancer group (7.29±4.47) and (14.71±6.19) respectively. There was a significant difference between studied groups regarding platelets (P >0.05); lowest platelet number was detected in cancer group (272.4±66.9). There was non-significant difference between studied groups regarding WBCs (P <0.05); highest WBCs number was detected in cancer group (8.05±2.3), There was a highly significant difference between studied groups regarding colonoscopy (P >0.001), There was a highly significant difference between studied groups regarding M2-Pyruvate kinase and Occult Blood (P >0.001), There was highly significant difference between M2-PK in cancer and control groups (p >0.001), There was significant difference between calprotectin in cancer and control groups (p >0.05), There was highly significant difference between occult blood in cancer and control groups (p >0.001), There was highly significant difference between Combined M2-PK and Calprotectin in cancer and control groups (p >0.001), There was highly significant difference between Combined M2-PK and Occult blood in cancer and control groups (p>0.001), There was highly significant difference between Combined M2-PK, Calprotectin and occult blood in cancer and control groups (p >0.001). Conclusion: Our study confirms that, Colorectal Cancer (CRC) increases with age and it is more common in male, CRP and ESR increase in CRC patients, Fecal M2PK, FC and FOBT in stool increase significantly in CRC patients, Sensitivity, specificity and accuracy of screening for CRC are highest in combination of fecal M2PK, occult blood in stool and FC tests.
Keywords: M2-Pyruvate kinase, Calprotectin, Occult Blood Test, Fecal Biomarkers, Early Detection of Colorectal Cancer
How to cite this article:
Atef Abo El-Soud Ali, Mohamed Gamal El Helbawy, Huda Saad Elmehily, Emad Mohamed Salem, Ahmed Abo Zaid Ahmed. Study the Role of Combined M2-Pyruvate kinase, Calprotectin and Occult Blood Test as Fecal Biomarkers for Early Detection of Colorectal Cancer .Open Journal of Gastroenterology and Hepatology, 2019, 2:21. DOI: 10.28933/ojgh-2019-11-2706
1. Mary C. White, ScD, Dawn M. Holman, MPH, Jennifer E. Boehm, MPH, Lucy A. Peipins, PhD, Melissa Grossman, MPH, and S. Jane Henley, MSPH ,Am J Prev Med. 2014 Mar; 46(3 0 1): S7–15.doi: 10.1016/j.amepre.2013.10.029
2. Morikawa T, Kato J, Yamaji Y, et al. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005;129:422-8.
3. Jessica Watson, Chris Salisbury, Jonathan Banks, Penny Whiting & Willie Hamilton British Journal of Cancer volume 120, pages 1045–1051(2019)Cite this article.
4. Winawer SJ1, Zauber AG, Ho MN, O’Brien MJ, Gottlieb LS, Sternberg SS, Waye JD, Schapiro M, Bond JH, Panish JF, et al.N Engl J Med. 1993 Dec 30;329(27):1977-81.
5. Connie L.Arnold,PhD;Alfred Rademaker,PhD;Michael S. Wolf,PhD,MPH; Dachao Liu,MS;Jill Hancock,BA;Terry C. Davis,PhD Third Annual Fecal Occult Blood Testing in Community Health Clinics Am J Health Behav. 2016;40(3):302-309
6. Jesús-Miguel Herrero,Pablo Vega,María Salve,Luis Bujanda and Joaquín Cubiella Symptom or faecal immunochemical test based referral criteria for colorectal cancer detection in symptomatic patients: a diagnostic tests study Herrero (2018) 18:155
7. Virender K. Sharma,M.D., Fred A. Corder, M.D.,Jennifer Fancher, B.S., and Colin W. Howden, M.D., F.A.C.G. Survey of the Opinions, Knowledge, and Practices of Gastroenterologists Regarding Colorectal Cancer Screening and Use of the Fecal Occult Blood Test THE AMERICAN JOURNAL OF GASTROENTEROLOGY Vol. 95, No. 12, 2000
8. JOHANN KARL, NORBERT WILD, MICHAEL TACKE, HERBERT ANDRES, URSULA GARCZAREK, WOLFGANG ROLLINGER, and WERNER ZOLG Improved Diagnosis of Colorectal Cancer Using a Combination of Fecal Occult Blood and Novel Fecal Protein Markers CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:1122–1128
9. Hisham K. Dabbous & Yosry Abd El-Rahman Mohamed & Runia F. El-Folly& Mohamed D. El-Talkawy & Hani E. Seddik & Dina Johar & Mohammed A. Sarhan Evaluation of Fecal M2PK as a Diagnostic Marker in Colorectal Cancer Journal of Gastrointestinal Cancer https://doi.org/10.1007/s12029-018-0088-1 2018
10. Kyung-Jae Lee MDa,Manami Inoue MDa,Tetsuya Otani MDa,Motoki Iwasaki MDa ,Shizuka Sasazuki MDa,Shoichiro Tsugane MDa Colorectal cancer screening using fecal occult blood test and subsequent risk of colorectal cancer: A prospective cohort study in Japan Cancer Detection and Prevention 31 (2007) 3–11
11. Mariann Rutka,Renáta Bor,Anita Bálint,Anna Fábián,ÁgnesMilassin, Ferenc Nagy,Zoltán Szepes,Mónika Sz4cs, László Tiszlavicz,Klaudia Farkas, and Tamás Molnár (2016)